glp 1 and gip mechanism of action The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect Beyond the pancreas: contrasting cardiometabolic
Description
The 1-pack (30-day supply) is 59.98 total - 29.99 per pack at 50% off
Tirzepatide has shown superior effects in controlling blood sugar levels as well as in promoting weight loss in clinical trials
eClinicalMedicine, 69, 102475
Key highlights: Once-daily oral administration No food or water restrictions No injections required ~12% mean weight loss in Phase 3 trials Improvements in cardiometabolic risk markers Indication: Approved for adults with obesity, or overweight individuals with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity
It acts on GIP receptor five times over GLP-1 receptor [50]
